Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil

Experimental studies have indicated the importance of cAMP and cGMP in modulation of peripheral sensory neurons leading to hyperalgesic response. The concentration of both depends upon the activity of phosphodiesterase, which is responsible for their degradation. The aim of the present study was to evaluate the effect of the PDE-5 inhibitor sildenafil on central or peripheral administration in formalin-induced hyperalgesia in rats. Sildenafil dose-dependently and significantly attenuated both the early and late phase of formalin-induced hyperalgesia on central administration. However, sildenafil on peripheral administration inhibited only the late phase of formalin-induced hyperalgesia in rats. The anti-nociceptive effect of sildenafil was blocked by L-NAME, a non-selective NOS inhibitor, and methylene blue (MB), a guanylate cyclase inhibitor, but sildenafil itself had little or no effect on the first phase of the formalin test in rats. The results from the present study indicates that sildenafil, besides peripheral actions, has a central anti-nociceptive effect, which may be due to activation of the NO-cGMP pathway, as this effect was blocked by L-NAME and MB. PDE-5 inhibitors could be considered as a new class of anti-nociceptive agents for future drug development.

[1]  S. Ferreira,et al.  November 2002 Extramurally Speaking , 2002, Environmental Health Perspectives.

[2]  P. Ruth,et al.  Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats , 2002, Neuroscience Letters.

[3]  C. S. Patil,et al.  Sildenafil-induced peripheral analgesia and activation of the nitric oxide–cyclic GMP pathway , 2001, Brain Research.

[4]  W. A. Prado,et al.  The dual effect of a nitric oxide donor in nociception , 2001, Brain Research.

[5]  M. Colasanti,et al.  The dual personality of NO. , 2000, Trends in pharmacological sciences.

[6]  R. Johns,et al.  Expression and action of cyclic GMP-dependent protein kinase Iα in inflammatory hyperalgesia in rat spinal cord , 1999, Neuroscience.

[7]  G. Lauretti,et al.  Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. , 1999, Anesthesiology.

[8]  F. Cunha,et al.  Pharmacological modulation of secondary mediator systems–cyclic AMP and cyclic GMP–on inflammatory hyperalgesia , 1999, British journal of pharmacology.

[9]  I. Goldstein,et al.  Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor: Research and Clinical Implications in Erectile Dysfunction , 1999, Trends in Endocrinology & Metabolism.

[10]  Kulkarni Sk,et al.  L-NAME, a nitric oxide synthase inhibitor, modulates cholinergic antinociception. , 1999 .

[11]  J. Levine,et al.  Nitric Oxide Signaling in Pain and Nociceptor Sensitization in the Rat , 1998, The Journal of Neuroscience.

[12]  K. Ferguson,et al.  Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. , 1998, Gene.

[13]  S. Kulkarni,et al.  Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging- and dizocilpine-induced learning impairment , 1998, Brain Research.

[14]  S. Phillips,et al.  Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). , 1998, Biochemical and biophysical research communications.

[15]  V. Granados-Soto,et al.  Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. , 1997, European journal of pharmacology.

[16]  T. Mashimo,et al.  Intrathecal administration of a new nitric oxide donor, NOC-18, produces acute thermal hyperalgesia in the rat , 1997, Journal of the Neurological Sciences.

[17]  D. Mitchison.  Mechanisms of Tuberculosis Chemotherapy , 1997 .

[18]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[19]  C. Lees,et al.  Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea , 1996, BMJ.

[20]  J. Arndt,et al.  Nitric oxide as a chemical link in the generation of pain from veins in humans , 1996, Pain.

[21]  H. Takagi,et al.  Effect of topical administration of l‐arginine on formalin‐induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation , 1994, British journal of pharmacology.

[22]  A. Ochoteco,et al.  Local Transdermal Glyceryl Trinitrate Has an Antiinflammatory Action on Thrombophlebitis Induced by Sclerosis of Leg Varicose Veins , 1994, Angiology.

[23]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[24]  S. L. Hart,et al.  Characterization of the novel nitric oxide synthase inhibitor 7‐nitro indazole and related indazoles: antinociceptive and cardiovascular effects , 1993, British journal of pharmacology.

[25]  G. Gebhart,et al.  Nitric oxide (NO) and nociceptive processing in the spinal cord , 1993, Pain.

[26]  J. Haley,et al.  Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse , 1992, Neuroscience Letters.

[27]  S. Ferreira,et al.  The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. , 1991, European journal of pharmacology.

[28]  S. Ferreira,et al.  Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. , 1990, European journal of pharmacology.

[29]  F. Porreca,et al.  Methodological refinements to the mouse paw formalin test. An animal model of tonic pain. , 1988, Journal of pharmacological methods.

[30]  Kjell Hole,et al.  The formalin test in mice: dissociation between inflammatory and non-inflammatory pain , 1987, Pain.

[31]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.

[32]  S. Ferreira,et al.  II - Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. , 1979, Prostaglandins.

[33]  J. E. Torres-López,et al.  Participation of peripheral and spinal phosphodiesterases 4 and 5 in inflammatory pain. , 2002, Proceedings of the Western Pharmacology Society.

[34]  S. Ferreira,et al.  Research Paper Mediators of Inflammation, 9, 25–30 (2000) , 2022 .

[35]  B. Przewłocka,et al.  Nitric oxide synthase inhibitors enhance the antinociceptive effects of oxotremorine in mice. , 1997, Polish Journal of Pharmacology.